PR93709

SINGAPORE, Dec. 15, 2021 /PRNewswire =KYODO JBN/ --

GenScript receives the award on COVID Management Initiative of the Year,

Biotechnology industry in the Singapore Business Review (SBR) Management

Excellence Award 2021. GenScript showed strong commitment and support to global

COVID-19 management including production of genes, proteins and peptides for

SARS-CoV-2 vaccine development around the world and launched first FDA EUA

(Emergency Use Authorization) neutralization antibody test kit, cPass™

SARS-CoV-2 neutralization antibody detection kit.

The SBR Management Excellence Awards is organized by Singapore Business Review

(SBR). Through the years, Singapore Business Review built its reputation and

credibility not only as a publication, but as a recognizing body. SBR launched

its first awards programme back in 2014 and has now become a recognised symbol

of excellence for companies throughout Singapore and the Southeast Asia region.

This year's winners were judged by an elite panel of judges from Ernst & Young

Advisory Pte. Ltd, KPMG Singapore, Deloitte Southeast Asia, BDO Consultants Pte

Ltd and Baker Tilly.

GenScript went through an intensive selection process by the judges based on

the initiative and effectiveness implemented from the company to navigate

current headwinds due to the pandemic and the impact it brought to the clients

and public. The launch of cPass™ SARS-CoV-2 neutralization antibody detection

kit is the key differentiator as it is part of the key for COVID-19 management.

cPass™ neutralization antibody test can estimate vaccine induced protection for

a population. At individual level, cPass™ result also shed light whether the

vaccine worked for the individual. Induction of high neutralization antibody

can confer protection and is a key success for vaccine developers. Since the

launch of the kit, many clinics in Singapore have incorporated cPass™ test as

part of the COVID-19 management and vaccine efficacy monitoring efforts.

"It's a great honor to receive this award from SBR, this is a real testament on

GenScript various efforts and solutions for combatting the pandemic, especially

cPass™ that has provided strong scientific and emotional confidence for us to

live with covid-19." said Dr. Li Yanfeng, head of IVD business development in

GenScript Asia Pacific.

With the recent emerging SARS-CoV-2 variant of concern (VoC), Omicron,

GenScript also plays a part to adapt cPass™ to detect neutralization antibody

to Omicron, providing Omicron RBD/S1/N protein & oligo for vaccine studies,

customized cell line for test kits development and lastly, to complement

cPass™, Pseudovirus assay for detecting neutralizing antibodies to Omicron as a

gold standard alternative.

GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is the world's leading

technology and service provider of life science R&D and manufacture. Built upon

its solid gene synthesis technology, GenScript Biotech is divided into four

major platforms including the life science service and product platform, the

biologics contract development and manufacturing organization (CDMO) platform,

the global cell therapy platform and the industrial synthesis biological

product platform.

GenScript Biotech was founded in New Jersey, US in 2002 and listed on the Hong

Kong Stock Exchange in 2015. GenScript Biotech's business operations span over

100 countries and regions worldwide with legal entities located in the US,

Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and

Ireland. GenScript Biotech provides premium, convenient and reliable services

and products for over 100,000 customers.

As of June 30, 2021, GenScript Biotech had more than 4500 employees globally,

over 40% of whom hold master's and/or Ph.D. degrees. In addition, GenScript

Biotech owns a number of intellectual property rights, including over 160

patents, over 600 pending patent applications and great numbers of trade

secrets.

Driven by the corporate mission of "making people and nature healthier through

biotechnology", GenScript Biotech strives to become the most trustworthy

biotech company in the world. As of June 30, 2021, GenScript Biotech's services

and products have been cited by 64,700 peer-reviewed journal articles worldwide.

For more information, please visit GenScript Biotech's official website

https://www.genscript.com

SOURCE:  GenScript

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=411070

   Caption: Representative of GenScript, Dr. Li Yanfeng who is the head of IVD business

development of GenScript Asia Pacific received the award from the Singapore

Business Review's Contributing Editor, Simon Hyett on 14th December 2021 at the

Conrad Centennial Hotel Singapore.